|
|
|
|
| TRADING CENTER |
48.20-0.10 / -0.21%
Genzyme Corporation (NASDAQ GS:GENZ)
47.87-0.33 / -0.69
After hours quote
Prev. Close:
48.30
Open:
48.15
High:
48.47
Low:
47.55
Volume:
2,331,000
Volume Avg.:
3,594,300
52wk Range:
47.09 - 73.75
Market Cap (mil):
12,791.46
P/E Ratio:
27.39
Dividend Yield:
N/A
| ANALYSIS-Health stock rally may extend as reform winds down - Reuters | |
| Genzyme: Hold Shares - Bloggingstocks.com | |
| 2009 Biotech Cheers and Jeers - MotleyFool.com | |
| Genzyme Founder Says CEO Must Go: Exclusive - at TheStreet.com | |
| Prospecting for Stocks: QLT - MotleyFool.com | |
| This Just In: Upgrades and Downgrades - MotleyFool.com | |
| Ready to rumble: Pfizer's generic biotech drug push could pit it against Amgen - DailyFinance | |
| Protalix Drug Advances - Analyst Blog - Zacks.com | |
| Positive Data on Genzyme's Campath - Analyst Blog - Zacks.com | |
| Genzyme Laboratory Recognized for Quality - Business Wire | |
| Robert J. Bertolini Elected to Genzyme's Board of Directors - Business Wire | |
| Genzyme's Mozobil Shows Promise in Chemosensitization - Business Wire | |
| Genzyme says combo approach aids leukemia patients - Reuters | |
| Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Secon... - Business Wire | |
| Critical Alerts For Capital One, Proctor & Gamble, FedEx, Genzyme, and Humana Rel... - PR Newswire |
| Last trade | Change/%change | P/E ratio | ||
|---|---|---|---|---|
| AMGN | Amgen Inc | 57.35 | 0.13 / 0.23% | 10.97 |
| GILD | Gilead Sciences Inc | 43.01 | -0.23 / -0.53% | 16.61 |
| CELG | Celgene Corporation | 56.80 | 0.51 / 0.91% | 68.43 |
Short Interest Date:
Nov 30 2009
Short Interest Shares:
3,835,576
Short Interest Ratio:
0.9
Float:
269,399,467
Short Interest as a % of Float:
1.4%
Average Daily Volume:
3,557,800
Outstanding Shares:
265,382,892
Genzyme focuses on developing, manufacturing, and marketing products to treat genetic disorders and other chronic debilitating diseases. The company's broad product and service portfolio addresses patients on a global scale, ranging from rare disease therapeutics to cancer diagnostics. Acquisitions ... (more)
| 2008 Revenue: | $4.6 B | Headquarters: Cambridge, MA |
| Employees: | 11,000 | CEO: Henri A. Termeer |
| Net Income: | $421.1 M | Industry: Biotechnology |
| Market Cap: | $12.8 B | Website: www.genzyme.com |
| Symbol | Price | Change/%Change | Prev. close | High | Low | Last Update | More Info |
|---|---|---|---|---|---|---|---|
| GENZ | 48.20 | -0.10 / -0.21% | 48.30 | 48.47 | 47.55 | Profile Chart News |
© 2009 Cable News Network. A Time Warner Company. All Rights Reserved.
Terms under which this service is provided to you. Privacy Policy. Advertising Practices.
Live Quotes automatically refresh, but individual equities are delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET.
* : Time reflects local markets trading time. † - Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Disclaimer
* : Time reflects local markets trading time. † - Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Disclaimer
| Copyright © 2009 BigCharts.com Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use. Intraday data is at least 20-minutes delayed. All times are ET. Historical, current end-of-day data, and splits data provided by Interactive Data Pricing and Reference Data. Fundamental data provided by Morningstar, Inc.. SEC Filings data provided by Edgar Online Inc.. Earnings data provided by FactSet CallStreet, LLC. |
